MGD024 vs Mipletamig

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Acute Myeloid Leukemia

Shared mechanism: CD123 x CD3 · full Acute Myeloid Leukemia pipeline

MGD024

Developed by MacroGenics

Phase 1 in Acute Myeloid Leukemiabispecific antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: November 2026 · NCT05362773 (registry estimate)

No aligned efficacy figure on record for this race.

Mipletamig

Developed by Aptevo Therapeutics

Phase 1 in Acute Myeloid Leukemiabiologic (registry-typed, subtype undisclosed)
Weak signal

NCT03647800 · Phase 1 · status unknown

This is an open-label, single-arm, dose-escalation and dose-expansion study with no control group and no blinding, so it cannot demonstrate a treatment effect on its own. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)

These results cover the monotherapy dose-escalation cohort only; combination-therapy expansion cohorts added later are not included. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: October 2027 · NCT06634394 (registry estimate)

Reported efficacy

Part 1 - Dose Escalation: Maximum Tolerated Dose (during first 28 to 35 days of treatment); Part 2 - Dose Expansion: Safety (during first 28 to 35 days of treatment): MTD not reached at a weekly dose of 60 mcg; infusion-related reactions occurred in 28.3% of patients and cytokine release syndrome in 21.7% (severe CRS 8.7%); Eight of 34 (23.5%) evaluable relapsed AML patients showed favorable responses and 3 of 6 (50%) evaluable relapsed MDS patients had a marrow CR. (not_applicable)

Result source: NCT03647800

Results for Acute Myeloid Leukemia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointMGD024Mipletamig
OS, median—Not reported—Not reported
Complete remission—Not reported—Not reported
Event-free survival, median—Not reported—Not reported
Duration of response, median—Not reported—Not reported

OS, median

MGD024
—Not reported
Mipletamig
—Not reported

Complete remission

MGD024
—Not reported
Mipletamig
—Not reported

Event-free survival, median

MGD024
—Not reported
Mipletamig
—Not reported

Duration of response, median

MGD024
—Not reported
Mipletamig
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

MGD024: no structured comparison results are available for Acute Myeloid Leukemia.

Mipletamig: no structured comparison results are available for Acute Myeloid Leukemia.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: MGD024's landscape · Mipletamig's landscape